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Abstract:
Retinal disorders such as retinitis pigmentosa, age‑related retinal degeneration, oxygen‑induced
retinopathy, and ischemia‑reperfusion injury cause debilitating and irreversible vision loss. While
the exact mechanisms underlying these conditions remain unclear, there has been a growing body
of evidence demonstrating the pathological contributions of oxidative stress across different cell
types within the eye. Nuclear factor erythroid‑2‑related factor (Nrf2), a transcriptional activator of
antioxidative genes, and its regulator Kelch‑like ECH‑associated protein 1 (Keap1) have emerged
as promising therapeutic targets. The purpose of this review is to understand the protective role
of the Nrf2‑Keap1 pathway in different retinal tissues and shed light on the complex mechanisms
underlying these processes. In the photoreceptors, we highlight that Nrf2 preserves their survival and
function by maintaining oxidation homeostasis. In the retinal pigment epithelium, Nrf2 similarly plays
a critical role in oxidative stabilization but also maintains mitochondrial motility and autophagy‑related
lipid metabolic processes. In endothelial cells, Nrf2 seems to promote proper vascularization and
revascularization through concurrent activation of antioxidative and angiogenic factors as well as
inhibition of inflammatory cytokines. Finally, Nrf2 protects retinal ganglion cells against apoptotic cell
death. Importantly, we show that Nrf2‑mediated protection of the various retinal tissues corresponds to
a preservation of functional vision. Altogether, this review underscores the potential of the Nrf2‑Keap1
pathway as a powerful tool against retinal degeneration. Key insights into this elegant oxidative
defense mechanism may ultimately pave the path toward a universal therapy for various inherited
and environmental retinal disorders.
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Introduction

O

xidative stress has been studied as
part of the pathogenesis of complex
retinal disorders such as age‑related macular
degeneration (AMD), diabetic neuropathy,
a n d g l a u c o m a . [1] R e a c t i v e o x y g e n
species (ROS) that induce oxidative stress
are produced naturally through aerobic
metabolism and exposure to environmental
influences such as ultraviolet light, smoke,
and heavy metals.[2] Fortunately, eukaryotic
cells have developed protective mechanisms
against ROS by promoting cellular
production of antioxidant molecules. [3]
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These defensive molecules prevent lipid,
DNA, RNA, and mitochondrial damage
that can potentially lead to cancer and
other diseased states.[4] Thus, hindrances
to the cellular transcription and translation
of these essential molecules and chronic
oxidative stress pose as serious threats to
the proper functioning of organ systems.
The nuclear factor erythroid‑2‑related
factor (NRF2)‑Kelch‑like ECH‑associated
protein 1 (KEAP1) pathway is an essential
biochemical mechanism that neutralizes
the oxidative damage caused by ROS. Nrf2
is a transcription factor that is upregulated
in times of oxidative stress, and KEAP1 is a
cytosolic inhibitory molecule that associates
How to cite this article: Ryu J, Gulamhusein H,
Oh JK, Chang JH, Chen J, Tsang SH. Nutrigenetic
reprogramming of oxidative stress. Taiwan J
Ophthalmol 2021;11:207-15.
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with NRF2 to keep it sequestered in the cytosol for
proteasomal degradation[1]. Nrf2 is encoded by NF‑E2
L2, which belongs to a subfamily of basic leucine
zipper transcription factors.[5] It is composed of 605
amino acids and contains 7 conserved regions.[6] Keap1
is encoded by the KEAP1 gene and has four domains
that span roughly 611 amino acids. The four domains
are called the N‑terminal broad complex, Tramtrack,
and Bric‑a‑brac and C‑terminal Kelch domain. The
collaboration between a double‑glycine repeat and the
C‑terminal region results in the formation of a six‑bladed
beta‑propeller structure that interacts with NRF2.[6]
Under homeostatic cellular conditions, NRF2 levels are
kept low via ubiquitination by Keap1; however, under
oxidative stressed environments, KEAP1’s inhibitory
capacity is diminished.[6] This leads to a sharp increase
in cytosolic NRF2 levels, and permits NRF2 to be
translocated to the nucleus where it effectively binds to
the Phase 2 antioxidant response element (ARE) within
a DNA promoter. The transcription of antioxidative
enzymes such as superoxide dismutase, catalase,
glutathione S‑transferase, quinone oxidoreductase,
heme oxygenase‑1 (HO‑1), thioredoxin (TRX) reductase,
and glutathione reductase is initiated to neutralize the
increased levels of intracellular ROS.[7]
The retina consumes more oxygen than any other tissue
in the human body on a per unit weight basis, and its
high metabolic state makes it particularly susceptible
to oxidative damage. [1] Research has shown that
photoreceptors, the retinal pigment epithelium (RPE),
retinal ganglion cells (RGCs), and retinal vascular
endothelial cells are the specific cellular structures
directly impacted by oxidative stress.[8‑10] Here, we
present a review of the NRF2‑KEAP1 pathway within
these cellular structures categorized by different disease
models.

Genetic Model for Retinitis Pigmentosa
Retinitis pigmentosa (RP) is a diverse group of inherited
retinal degenerations that cause progressive vision
loss. Affecting 1 in 4000 individuals, RP is caused by
over 3100 mutations in >70 genes with varying clinical
manifestations depending on the underlying pathogenic
mutation.[11] Despite genetic and clinical heterogeneity,
RP is characterized by the same pathology: a wave of
rod death followed by secondary cone degeneration.
More recently, it has been suggested that oxidative stress
contributes to secondary cone death in RP. Healthy
photoreceptors are metabolically active cells that
consume high levels of oxygen.[12] As such, the death of
rods, which account for >90% of photoreceptors, leads
to a hyperoxidation state that causes lethal oxidative
damage on the remaining cones.[13,14] Given the genetic
etiology of RP, genetic manipulation represents a
208

powerful tool to model disease pathogenesis and
progression. Here, we provide a summary of studies
that have implemented a genetic approach to investigate
the functional role of the NRF2‑KEAP1 pathway in RP.
A significant number of studies involving preclinical
RP models have relied on adeno‑associated
virus (AAV)‑mediated overexpression. Notably,
NRF2 upregulation significantly improved cone
survival and structure in two distinct mouse models
for Pde6‑associated RP: Pde6Brd1/rd1 and Pde6Brd10/rd10.[15]
Consistent with the observed morphological protection,
AAV‑NRF2 also drastically delayed the decrease in
visual acuity and preserved retinal activity in rd10 mice.
Interestingly, AAV‑NRF2 was found to significantly
reduce lipid peroxidation in rd10 retinas, suggesting that
NRF2‑mediated rescue of retina function and structure in
RP may be related to a reduction in oxidation [Figure 1A].
Similar rescue effects were noted in a mouse model
for Rho‑associated RP: Rho −/−mice. AAV‑mediated
overexpression of NRF2 significantly improved cone
viability, which corresponded to preservation of the
cone outer segment (OS). This neuroprotective effect
was further corroborated in another Rho‑associated RP
model: RhoP23H/+.[16] Importantly, intravitreal injection
of protein kinase R‑like endoplasmic reticulum
kinase (PERK) inhibitor GSK2606414A increased cell
death while reducing NRF2 activation, suggesting that
PERK confers protection against photoreceptor death via
the NRF2‑KEAP1 pathway in RP [Figure 1B].

Age‑Related Retinal Degeneration
AMD is a prevalent eye condition that is characterized
by the progressive degeneration of the outer retina. One
of the clinical hallmarks of this condition is the presence
of drusen, which is thought to cause vision loss via
geographic atrophy and choroidal neovascularization.
While the mechanism of drusen formation remains
unclear, they have been characterized as depositions of
lipid and proteins between the basal lamina of the RPE
and Bruch’s membrane.[17‑19] Prominent components
include byproducts of oxidative modification of fatty
acids, implicating the pathological role of oxidative
stress in AMD.[20,21]
Zhao et al. revealed that Nrf2 knockout mice exhibited
higher levels of lipofuscin accumulation and increased
incidence of choroidal neovascularization.[22] Ocular
funduscopic examination revealed an earlier onset
of drusen and atrophic RPE lesions in Nrf2 knockout
mice. Interestingly, there was also an accumulation
of photoreceptor OS and autophagy‑related vacuoles
within the RPE in an age‑dependent manner,
indicating a lysosome‑related defect. The buildup of
Taiwan J Ophthalmol - Volume 11, Issue 3, July-September 2021

Figure 1: Protective role of the NRF2‑KEAP1 pathway in genetic models of RP. (A) Nrf2 overexpression has shown to increase cone survival, preserve outer segment/inner
segment structures, improve visual acuity, and enhance retinal activity by inhibiting lipid peroxidation. (B) PERK‑mediated activation of NRF2 was found to inhibit photoreceptor
degeneration, increase cone viability, and maintain outer segment structures. PERK = protein kinase R‑like endoplasmic reticulum kinase, NRF2 = Nuclear factor erythroid‑2‑related
factor, KEAP1 = Kelch‑like ECH‑associated protein 1, RP = Retinitis pigmentosa

poly‑ubiquitinated proteins underneath the RPE, in
turn, suggested an impairment in lysosome‑mediated
degradation of oxidatively damaged proteins. Altogether,
these results indicate that NRF2 may protect the outer
retina against age‑related degeneration by maintaining
oxidation homeostasis via lysosome‑dependent
degradation [Figure 2A].
It has also been suggested that NRF2 dysregulation
may pathologically contribute to AMD by disrupting
mitochondrial trafficking and homeostasis. [23,24]
Supporting this model, O’Mealey et al. revealed that NRF2
and KEAP1 form a complex with the mitochondrial outer
membrane histidine phosphatase PGAM5 to maintain
mitochondrial motility through proteasome‑mediated
degradation of MIRO2,[25] a mitochondrial GTPase that
connects the mitochondria to microtubules. Notably,
NRF2 and PGAM5 but not KEAP1 are necessary to
facilitate transportation of the mitochondria in RPE‑1
cells. While the functional implications remain unclear,
studies have demonstrated that the mitochondria undergo
retrograde movement toward the centrosome in response
to oxidative stress.[25] As such, age‑related decline of
NRF2 may exacerbate mitochondria‑derived ROS in the
RPE, ultimately driving retinal degeneration [Figure 2B].

death across various animal models including mice
and rats.[26,27] More specifically, chromophores within
photoreceptors and the RPE absorb light and reach
an excited state that rapidly interacts with molecular
oxygen, leading to a fatal elevation of ROS production.[25]
Consistently, there is an increasing body of evidence,
indicating that visual light pathologically interacts with
oxidative stress and contributes to the development
and progression of retinal disorders including AMD
and RP.[28,29] As such, light‑induced retinopathy (LR)
has received attention as a valuable disease model to
investigate the pathological role of oxidative stress in the
eye. Here, we provide an overview of how the LR model
has been used to elucidate the function and mechanism
of the NRF2‑KEAP1 pathway in mitigating oxidative
stress in photoreceptors and RPE cells.

Light‑Induced Retinopathy

The cytoprotective effect of the NRF2‑KEAP1 pathway
on light‑induced damage and death in the retina has
been well characterized in vitro. Chen et al. found
that light damage increased ROS production and
cell death in a cultured cone‑like 661W cell line in
an exposure‑dependent manner. [30] This effect was
significantly exacerbated following siRNA mediated
knockdown of Nrf2, indicating that NRF2 promotes
photoreceptor survival by countering light‑induced
oxidative stress.

The exposure of bright light is known to cause
photo‑oxidative stress, leading to photoreceptor

To investigate phototoxicity of retinoids in RPE
cells, Gao and Talalay treated ARPE19 cells with

Taiwan J Ophthalmol - Volume 11, Issue 3, July-September 2021
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Figure 2: Protective role of the NRF2‑KEAP1 pathway in age‑related retinal degeneration. (A) Age‑related decline of NRF2 may pathologically contribute to retinal degeneration
by disrupting mitochondrial‑associated motility and metabolism of reactive oxygen species. (B) NRF2 mitigates drusen development, geographic atrophy, and choroidal
neovascularization by enhancing lysosome‑mediated lipid metabolism in the retinal pigment epithelium. NRF2 = Nuclear factor erythroid‑2‑related factor, KEAP1 = Kelch‑like
ECH‑associated protein 1

varying concentrations of all‑trans‑retinaldehyde,
all‑trans‑retinol, or all‑trans‑retinoic acid.[31] Exposure
to ultraviolet A (UVA) light induced significant cell
death. Sulforaphane activation of NRF2, in turn, offered
protection against retinaldehyde‑mediated phototoxicity
in a dose‑dependent fashion as shown by the increase
in cell survival. Further investigation using embryonic
fibroblast cell lines from transgenic mice revealed that
NRF2‑mediated protection against UVA exposure
was directly correlated with the activities of two
NRF2‑regulated antioxidant proteins GSH and NAD (P)
H quinone dehydrogenase 1 (NQO1). Later, Tanito et al.
demonstrated that NRF2 binds to the ARE sequence in
the TRX promoter in cultured human K‑1034 RPE cells.[32]
Altogether, these findings suggest that NRF2 confers
cytoprotection against photo‑oxidative stress in RPE
cells via TRX, GSH, and NQO1 [Figure 3A].
To further characterize NRF2‑mediated neuroprotection
in vivo, studies have relied on AAV mediated
overexpression and pharmacological activators of
NRF2 [Figure 3B]. AAV‑Nrf2 injection in mice subjected
to light damage exhibited full functional recovery
and even increased retinal thickness compared to
uninjected controls. [33] Consistently, monomethyl
fumarate (MMF)‑induced upregulation of NRF2
prevented ONL and retinal separation and preserved
retinal function in mice.[34] In April 2020, MMF received
the Food and Drug Administration approval to treat
relapsing forms of multiple sclerosis (MS),[35] supporting
the safety and efficacy of NRF2 as a therapeutic
target. However, the exact process of MMF‑NRF2’s
210

neuroprotection remains unclear. There is a growing
body of evidence, suggesting that MMF may alleviate
neurodegeneration by modulating immune responses
and antioxidative pathways. Previous studies have
shown that MMF reduces neuronal excitotoxicity
by limiting glutamate release from lymphocytes,[33]
which is known to play a role in MS. Moreover,
MMF‑mediated activation of HO‑1 and nicotinamide
adenine dinucleotide phosphate (NADPH) via NRF2 was
found to benefit inflamed human brain endothelial cells
by decreasing inflammation and monocyte migration.[36]
Further preclinical and clinical studies are warranted to
investigate whether these protective mechanisms are
conserved within the retinal microenvironment.
More recently, light damage was shown to increase Kitl
expression in photoreceptors, triggering Ho1 expression
via NRF2 activation.[37] Disruption of KIT signaling
worsened light‑induced damage to retinal function and
structure, while AAV‑mediated KIT overexpression
partially rescued photoreceptor viability and activity.
Altogether, these findings suggest that KIT is necessary
and sufficient for NRF2‑mediated protection.

Oxygen‑Induced Retinopathy
The critical role of oxidative stress on the regulation
of revascularization within the retina has been well
established. A low and transient level of ROS is known
to promote angiogenesis;[38,39] in contrast, excessive
oxidative stress has been found to negatively impact
revascularization in retinal disorders including ischemic
Taiwan J Ophthalmol - Volume 11, Issue 3, July-September 2021

Figure 3: Protective role of the NRF2‑KEAP1 pathway in light‑induced retinopathy. (A) NRF2 overexpression via sulforaphane treatment delays UVA‑induced retinal degeneration
by promoting the production of TRX, NQO1, and GSH in the retinal pigment epithelium. (B) NRF2 overexpression via RS9, MMF, and BE2 treatment confers protection against
phototoxicity by inducing expression of HO‑1 in photoreceptors. A positive feedback loop between Kit ligand (KITL) and NRF2 has been reported in the context of UVA damage.
TRX: Thioredoxin; NQO1 = NAD(P)H quinone dehydrogenase 1, GSH = Glutathione, HO‑1 = Heme oxidase 1, NRF2 = Nuclear factor erythroid‑2‑related factor, KEAP1 = Kelch‑like
ECH‑associated protein 1

retinopathy of prematurity, ischemia‑reperfusion
(I/R),[40‑42] and diabetic retinopathy.[42,43]
Oxygen‑induced retinopathy (OIR) has emerged as a
powerful tool to model how oxidative stress contributes
to pathological vascularization. Although various OIR
protocols have been developed across different species,
a protocol by Smith et al. has become established
as the golden standard due to its reproducibility
and accuracy. [44] Phase I involves subjecting mice
to hyperoxia (75%) at postnatal 7 (P7) until Phase II
when the mice are returned to normoxia at P12. Aptly
described as vaso‑obliterative, Phase I causes blood
vessels to constrict and die in the central retina. The
lack of sufficient vasculature, in turn, induces hypoxia
within the central ischemic retina during Phase II.[45]
The alternation between hyperoxic and hypoxic states,
in turn, drives a drastic surge in pro‑angiogenic factors
and ROS,[46] triggering the development of maladaptive
pathologic neovascularization. Here, we describe
how the OIR model has offered critical insight into
the role of the NRF2‑KEAP1 pathway in pathological
vascularization.
Wild‑type (WT) and transgenic Nrf2 knockout mice
were subjected to OIR protocols. During Phase I,
hyperoxia‑treated WT mice exhibited reduced secondary
vascular networks compared to mice raised in normoxic
conditions.[47] In contrast, there were no secondary or
Taiwan J Ophthalmol - Volume 11, Issue 3, July-September 2021

deep capillaries in all the Nrf2 knockout mice irrespective
of their oxygen treatment. [48] During Phase II, Nrf2
knockout mice exhibited a larger avascular area in the
retina with pathological neovascularization and reduced
rod activity.[49] These results collectively show that NRF2
plays a critical role in not only vascularization but also
revascularization and functional vision.
Thus far, several mechanisms for NRF2‑mediated
protection in vascularization have been proposed
[Figure 4]. There was a consistent and significant
reduction in Nqo1 mRNA expression in Nrf2 knockout
mice compared to WT mice throughout Phase II.[48]
Interestingly, Nrf2 ablation also elevated protein and
mRNA expression of NADPH oxidase 2 (Nox 2), one
of the four major NOXs responsible for generating
ROS. Pharmacological inhibition of NOX2 rescued
vascularization in retinas with Nrf2 ablation. Given
that a more recent study has shown that NQO1 may
modulate NOX activity,[50] these findings suggest that
NRF2‑mediated activation of NQO1 inhibits NOX2 to
mediate proper revascularization.[51]
Another downstream target impacted during Phase
II by Nrf2 ablation was Sema6A, an axon guidance
gene.[51] More specifically, SEMA6A protein and mRNA
significantly increased in the central ganglion cell layer,
which was abrogated by hypoxia inducible factor 1
alpha (HIF‑1a) suppression. Notably, Lentivirus‑mediated
211

Figure 4: Protective role of the NRF2‑KEAP1 pathway in oxygen‑induced retinopathy. NRF2 promotes proper vascularization through both cell type‑specific and general mechanisms.
In retinal ganglion cells, NRF2 inhibits SEMA6a via HIF‑1A stimulation. In Muller cells, NRF2 suppresses inflammatory cytokines. NRF2 was also found to maintain oxidation
homeostasis by inhibiting ROS via NQO1 stimulation. Finally, VEGF has shown to play a multifaceted role in preserving vascularization and preventing pathological neovascularization
through NRF2‑mediated activation and inhibition, respectively. HIF‑1A: Nox 2 = NADPH oxidase 2, NQO1 = NAD(P)H quinone dehydrogenase 1, HIF‑1a = Hypoxia inducible
factor 1 alpha, TNF‑A = Tumor necrosis factor alpha; IL‑1B = Interleukin 1 beta, MCP‑1 = Monocyte chemoattractant protein 1, ICAM‑1 = Intercellular adhesion molecule 1,
VEGF = Vascular endothelial growth factor, NRF2 = Nuclear factor erythroid‑2‑related factor, KEAP1 = Kelch‑like ECH‑associated protein 1, ROS = Reactive oxygen species

knockdown of Sema6A in the inner retina of Nrf2
knockout mice significantly reduced the avascular retinal
area. Altogether, these results suggest that NRF2 may
promote reparative angiogenesis by inhibiting SEMA6A
via HIF‑1A.
The positive feedback loop between inflammation and
angiogenesis has been suggested to prevent proper
revascularization.[49,52] Notably, Nrf2 knockout was
found to elevate expression of inflammatory cytokines
tumor necrosis factor‑alpha and interleukin (IL)‑1beta in
OIR,[48,53] suggesting that NRF2 may normally suppress
inflammatory mediators. Interestingly, synthetic
triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28oyl]imidazole (CDDO-Imidazolide, CDDO-Im) induced
activation of NRF2 attenuated the expression of IL‑1B,
monocyte chemoattractant protein 1, and intercellular
adhesion molecule 1 in Muller glial cell culture.[47] NRF2
deletion in the neuroretina and Muller cells, in turn,
significantly decreased revascularization,[54] suggesting
that NRF2 may improve revascularization by inhibiting
inflammatory cytokine activation in Muller cells.
Vascular endothelial growth factor (VEGF) is a critical
factor in endogenous angiogenesis, and it has been
previously suggested that the hyperoxia‑induced
vaso‑obliteration may be caused by the suppression of
VEGF expression.[55,56] Consistently, dh404 treatment
restored VEGF mRNA and protein levels in Phase I
OIR, which corresponded to reduced vaso‑obliteration
in Phase I. [55] At the same time, intraperitoneal
injection of Nrf2 activator RS9 reduced the avascular
212

area and neovascularization while simultaneously
downregulating VEGF and upregulating NRF2 in
Phase II.[57] Altogether, these findings suggest that NRF2
modulation of VEGF has a multifaceted role of both
preserving vascularization and inhibiting pathological
neovascularization.

Ischemia‑Reperfusion Injury
I/R injury is another important disease model that is
highly relevant to the study of oxidative stress in retinal
ischemia and revascularization. Similar to the OIR
model, I/R injury is characterized by two distinct phases
and leads to severe oxidative stress and inflammatory
damage. However, we chose to distinguish between these
two models for two reasons. The first is the difference in
how ischemia is induced: while OIR relies on hyperoxia,
retinal I/R injury is caused by hypoxia by raising the
intraocular pressure via an intraperitoneal injection. This
causes a halt in the inner retinal blood flow (ischemia),
which represents Phase I. After a short, designated period
of time, circulation is restored (reperfusion) during Phase
II of the protocol. The second reason for separating I/R
from OIR lies in its use as a disease model.[56] Beyond its
relevance to vascularization‑related processes, I/R injury
has been widely used to study the effects of neuronal
injury in the retina, especially RGC loss. As such, we will
provide an overview of how I/R model has been used
to understand the role of the NRF2/KEAP1 pathway in
ischemia‑driven pathology, with particular emphasis on
its effect in the inner retina.
Taiwan J Ophthalmol - Volume 11, Issue 3, July-September 2021

Xu et al. demonstrated that Nrf2‑deficient mice were
found to have an earlier onset of RGC death after I/R.[42]
The higher levels of apoptotic DNA cleavage after I/R
in these mice suggested that NRF2 mediates protection
against apoptotic cell death in RGCs [Figure 5]. The use
of pharmacological NRF2 activators further corroborated
this relationship. Daily intraperitoneal injections of
CDDO‑Im and MMF before and after I/R significantly
improved ganglion cell layer (GCL) neuronal cell
survival in WT but not Nrf2 knockout mice.[40,42] At the
same time, NRF2‑induced protection of RGC extends
beyond I/R injury. More specifically, AAV‑NRF2 gene
therapy preserves RGCs after optic nerve crush while
Nrf2 knockout exacerbates optic neuritis and RGC death
in a well‑established model of MS.[15,57]
Importantly, the neuroprotective effect of NRF2
correlates to improved retinal function. Cho et al. showed
that MMF‑mediated activation of NRF2 significantly
enhanced retinal function in WT but not Nrf2 knockout
mice after I/R.[40] Consistently, the NRF2‑mediated
cytoprotection of retinal neurons was conserved in a rat
model of I/R. Treatment with CPUY192018 and 18e, two
potent NRF2‑KEAP1 protein‑protein inhibitors improved
retinal function as determined by a virtual optomotor
system and spatial frequency, respectively.[58,59]

Conclusion
Oligogenic retinal disorders including AMD, glaucoma,
and diabetic retinopathy are caused by a broad range of
factors that lead to the degeneration of different parts of
the retina. Despite the clinical and causal heterogeneity,

these conditions share a similar pathology that revolves
around oxidative stress. The NRF2‑KEAP1 pathway is
a well‑established defense mechanism against oxidative
stress, making it an attractive therapeutic target. Here, we
provide a review of how different disease models have
offered critical insight into the role of the NRF2‑KEAP1
pathway in various retinal tissues. More specifically,
genetic models of RP and LR models have revealed
that the NRF2‑KEAP1 pathway offers structural and
functional protection for photoreceptors. Age‑related
degeneration models and LR models, in turn, have been
used to elucidate NRF2‑mediated preservation of RPE
cells. Finally, OIR and I/R models have demonstrated
the cytoprotective role of the NRF2‑KEAP1 pathway
in vascularization and GCL neuronal cell survival,
respectively. Across many of these disease models,
NRF2 activators including MMF were used to show
the therapeutic benefits of the NRF2‑KEAP1 pathway.
The ophthalmic applications of pharmacological
supplementation of NRF2 activators thus warrant
further study. Altogether, the NRF2‑KEAP1 pathway
represents a promising direction for future therapies, and
a deeper understanding of its role will be a critical step
toward achieving universal protection against retinal
degeneration.
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